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Abstract 
Introduction: The frequency of antibiotic-associated diarrhoea (AAD) could be as 
high as 60% during hospital outbreaks. Little is known about the use of antibiotics 
and the extent of AAD in spinal cord injury (SCI) patients. Our aim was to (1) record 
the use of antibiotics; (2) establish the prevalence of AAD and Clostridium difficile 
associated diarrhoea (CDAD) and; (3) assess if there was any seasonal variation in 
antibiotic use and incidence of AAD. 
Methods: A retrospective audit was conducted in a British SCI centre during October 
2014 to June 2015. Data was collected using a standardised questionnaire. We define 
AAD as 2 or more watery stools type 5, 6 or 7 (Bristol stool scale) over 24 hours. 
Results: Three-hundred-and-nineteen adults (mean age: 55.9 years, 29.2% female) 
with SCI (58.2% tetraplegia; 43.7% complete SCI) were included. Of 70 (21.9%) 
patients on antibiotics, the top three indications for antibiotics were urinary-tract 
infections, infected pressure ulcers and other skin-infections. Seventeen of 78 (21.8%) 
developed AAD and three of 319 (0.94%) developed CDAD. AAD was more 
common in the summer season than in spring, autumn and winter. (47.1%, 10.0%, 
10.0%, 23.8%, p=0.025). AAD was associated with older adults greater than 65 years. 
(70.6% v 23.8%, p=0.007) Polypharmacy and the summer season were identified as 
independent predictors for AAD.  
Conclusion: This survey found AAD is common in SCI patients and may be a risk 
factor for a poorer outcome and increased hospital costs. A multicenter study is 
underway to establish the incidence and risk factors for AAD. 
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Introduction 
Antibiotic associated diarrhoea (AAD) is a common complication of antibiotic 
treatment. The disturbance of normal gut microbiota, especially after antibiotic use, is 
thought to predispose patients to pathogenic bacterial colonisation
1,2
  It is reported 
that three predominantly opportunistic pathogens including Clostridium difficile (C. 
diff), Staphylococcus aureus and Clostridium perfringens were associated with AAD
3
. 
AAD is described as unexplained diarrhoea that occurs in association with antibiotic 
administration.
3
 Diarrhoea is thought to be clinically significant if there are more than 
3 loose stools per day
4,5
 although a recent survey in SCI centres found the definition 
of diarrhoea and diagnostic criteria of C. diff infection (CDI) vary among spinal cord 
injury (SCI) centres.
6
 In addition, diarrhoea after SCI is often complicated by spurious 
diarrhoea due to underlying constipation.  
 
AAD occurs in about 5-25% of adult patients upon administration of 
antibiotics.
4
 C. diff associated diarrhoea (CDAD) occurs most often as a consequence 
of disruption of the gut microbiota following a broad-spectrum of antibiotic treatment. 
CDAD accounts for 20-30% of AAD, although some estimates are more 
conservative.
3,7
 In the majority of patients, full recovery is usual, although particularly 
elderly and frail patients may suffer loss of dignity, become seriously ill with 
dehydration as a consequence of the diarrhoea, and may progress to develop life 
threatening pseudomembranous colitis.  
 
Exposure to antibiotics within the previous three months is thought to be one 
of the most important risk factors for developing CDAD. Other well-recognised risk 
factors include age
9
, hospitalisation
9
, severity of underlying illness
9
, use of proton 
pump inhibitors
9
, malnutrition risk
10
 and seasonal variation.
11
    However, this may 
not be a characteristic that is shared among all patient groups.
12
 SCI patients are at 
higher risk of hospital acquired infections because of longer hospital stay for acute 
and rehabilitation stay.
12
 Newly-injured SCI patients require anticoagulation therapy 
to prevent venous thromboembolism. This increases the risk of gastric ulcers, 
therefore patients commonly receive a proton pump inhibitor (PPI) to protect the 
stomach against this adverse effect. Literature reports show that patients on PPIs have 
a relative risk of 69% of contracting C. diff against patients who are not taking the 
medication.
13
  In addition, increased use of invasive devices such as urinary catheters 
4 
increases the risks of infections. 
12 
AAD / CDAD can complicate any pressure ulcer 
management as it contributes moisture and bacteria. Recurrent diarrhoea also depletes 
the body of electrolytes which are key in wound healing such as potassium, or during 
chronic episode micronutrients such as magnesium and zinc.
14
 This is through direct 
loss, but also via malabsorption. Diarrhoea causes dehydration and malnutrition with 
further medical consequences.
15
 
 
 
The objective of this study was to (1) record the use of antibiotics; (2) 
establish the prevalence of AAD and CDAD and; (3) assess if there is any seasonal 
variation on infections and prevalence of AAD in a UK leading SCI centre. 
 
Methods 
This was a one year, retrospective, point-prevalence study. The data was collected 
from the National Spinal Injuries Centre at Stoke Mandeville Hospital, UK during 
October 2014 to June 2015. A 30 item cross-sectional questionnaire was distributed to 
the SCI centre’s clinicians. The questionnaire consisted of three sections: the first 
section was collecting individual’s baseline demographics, level and cause of SCI, 
presence of co-morbidities and routine blood biochemistry. The second section was 
collecting the number of medications and whether patients are on antibiotics. The 
indication for starting antibiotics, dose, route and frequency of antibiotics, use of 
proton pump inhibitor, H2 blocker, laxatives and anti-diarrhoeal agents were also 
collected. The last section was aimed at occurrence of diarrhoea and C. diff infection.   
 
We define AAD as 2 or more watery stools type 5, 6 or 7 (Bristol stool scale) 
over 24 hours.
5
 CDAD was diagnosed by a positive C. difficile toxin A and B in stool 
samples. 
 
Formal ethical permission to conduct the study was not required by the 
Institution’s review board as this was considered to be a clinical audit not involving 
active patient participation.
16
 The questionnaires were approved by the local clinical 
audit departments. In addition, we tested  the pilot questionnaire on three patients to 
assess the content and time required to complete the questionnaire; feedback from this 
5 
guided the drafting of the final version of the questionnaire (supplementary 
information). Completed questionnaires were anonymised prior to data input and 
analysis.   
 
The intensity of antibiotic exposure was used to categorise patients into those 
on relatively low-risk antibiotics (metronidazole and parenteral aminoglycosides), 
those on ‘medium-risk’antibiotics (tetracyclines, sulphonamides, macrolides and 
quinolones) and those on ‘high-risk’ antibiotics (aminopenicillin and cephalosporins), 
using the criteria described elsewhere.
17
  
 
In order to analyse the seasonal variation of AAD, CDAD and infections 
caused, we collected  data from all in-patients from 4 different time points (1) 1
st
 
October 2014: Autumn; (2) 1
st
 February 2015: Winter; (3) 6
th
 April 2015: Spring and; 
(4) 1
st
 June 2015: Summer. 
 
Statistical analysis 
The prevalence of AAD and CDAD was obtained by dividing the total number of 
patients that had developed AAD / CDAD by the total number of patients studied 
during the study period. Descriptive statistics were used to calculate response 
frequency. Data was reported as mean (s.d.) or median (ranges).  Χ2 tests were used to 
compare differences in the distribution of qualitative variables. Differences in 
quantitative variables, according to their distribution, were analysed by the parametric 
t test or the non-parametric Mann–Whitney test. Univariate linear regression analysis 
of the occurrence of AAD was then undertaken. Those which were significant 
(P<0.05) were entered into a multivariate analysis to determine which made a 
significant unique contribution to AAD. As only a small number of CDAD, multiple 
binary logistic regression analysis was used to determine significant predictors for 
AAD, and effect estimates were presented as the OR and 95% CI. For all tests, a P 
value of 0·05 or less or when the 95% CI for OR did not exceed 1·0 was considered 
as significant. Statistical analysis was performed using the Minitab statistical software 
(version 15.0; Minitab, Inc.) and SPSS (version 19; IBM Corporation). 
 
 
 
6 
Results 
A total of 319 adults (mean age: 55.9 years, 29.2% female) with SCI (58.2% 
tetraplegia; 43.7% complete SCI) were studied. Seventy (24.3%) patients were on 
antibiotics, the top five indications for antibiotics were urinary-tract infections (n=16, 
20.5%), pressure ulcers / wound infections (n=12, 15.6%), skin-infection (n=12, 
15.6%), nail infection (n=8, 10.4%) and osteomyelitis (n=7, 9.1%). (Table 1) Urinary 
tract infections were found to be more common in the autumn season (50%) when 
compared with winter (14.3%), spring (5%) and summer (11.8%), respectively 
(p<0.001). (Table 1) 
 
Seventeen of 78 patients on antibiotics (21.8%) developed diarrhoea (AAD). 
This is significantly higher when compared to those not on antibiotics (5.8%). (Table 
2) Patients who received antibiotics tended to take more medications (13 v 10, 
p<0.01) and had a higher c-reactive protein (18 v 8.1, p<0.001). (Table 2) No 
significant difference was found in the number of older adults, severity of SCI 
(number of cervical injury and number of complete SCI), serum albumin level, mean 
white cell counts, proportions of patients using proton pump inhibitor, H2 blocker, 
laxatives and anti-diarrhoeal agents. (Table 2)  
 
AAD was not significantly associated with longer duration of antibiotic 
therapy (mean duration, 16 days for patients with AAD vs 14 days for those without 
AAD, p= 0.610). (Table 3) 44.2% patients received multiple antibiotics. Patients 
tended to develop AAD if they were on multiple antibiotics (70.6% in patients with 
AAD vs 35.8% for those without AAD, p=0.023). The most frequently used 
antibiotics regimen that were associated with AAD were tazocin, clindamycin and 
flucoxacillin. 52.9% of patients that had developed AAD were found to be on high-
risk antibiotics  compared to 37.7% of patients on low-risk antibiotics, p=0.397. 
(Table 3) 
 
AAD was more common in the summer season when compared to spring, 
autumn and winter. (47.1%, 10%, 10%, 23.8%, p=0.025). (Table. 1) AAD was 
associated with older adults aged 65 years or above (70.6% v 31%, p=0.003) and 
tetraplegia (76.5% v 44.4%, p=0.021). In addition, patients with AAD tended to have 
a lower serum albumin level (24.5g/L v 31.5g/L, p<0.001). 
7 
The binary multivariate logistic regression analysis identified the 
polypharmacy (OR 1.17, 95% CI 1.00, 1.37) and summer season (OR 14.45, 95% CI 
1.17, 178.1) as the unique risk factor for AAD.  (Table 4) 
 
As only a small number of patients developed CDAD (n=3), this form of 
analysis was deemed inappropriate for the CDAD data. 
 
Discussion 
The purpose of this study was to establish the prevalence and assess whether seasonal 
variation affects the occurrence of AAD and CDAD among SCI patients. The 
prevalence of AAD was 22.1% and CDAD was 1.3%.  This is comparable with the 
reported prevalence of AAD
3
 and CDAD
7
 in general populations and previous studies 
conducted in SCI centres.
15
 Our study found that summer season and polypharmacy 
are unique predictors for AAD.   
 
Antibiotic administration causes alternation in intestinal microbiota, which 
results in the loss of physiologic processes involving the metabolism of nutrients. 
Under normal circumstances, non-absorbable carbohydrates are metabolized by 
anaerobic colonic bacteria as an energy source. As metabolism occurs, lactic acid and 
short-chain fatty acids (SCFAs) such as butyrate are produced. Fluid, electrolytes, and 
SCFAs are absorbed, with only small amounts of these organic acids remaining in the 
colon. Undigested non-absorbable carbohydrates, organic acids and cations 
accumulate, causing osmotic diarrhoea. Multiple antibiotics have been implicated in 
reduced colonic bacterial carbohydrate metabolism. Clindamycin has been shown in 
vitro to decrease faecal carbohydrate metabolism as well as concentrations of SCFA. 
Ampicillin, metronidazole, dicloxacillin, and erythromycin have also been implicated 
in causing reduced faecal concentrations of SCFA.
18
  Our data found a higher 
proportion of patients that developed AAD were on higher-risk antibiotics but we 
failed to find any statistical association. 
  
Another pathway that could be significantly affected by antibiotic 
administration involves the synthesis of primary bile salts. If bile salts are not 
absorbed in the small bowel, bile salts will dehydroxylated to secondary bile acids by 
bacteria in the colon. These secondary bile acids are potent colonic secretory agents, 
8 
and presence in the colon can cause secretory diarrhoea. In addition, the increase in 
colonic pH caused by decreased carbohydrate metabolism results in increased 
solubility of dehydroxylated secondary bile salts, so these mechanisms may actually 
work in synergy to cause AAD.
18 
 
The present study found the prevalence of CDAD was low in comparison to 
previous reports. 
6,10,11
 The fall in CDAD prevalence could be due to the continuing 
year-on-year fall of overall Clostridium difficile infection cases in British hospitals. 
Indeed, the overall CDI rate for England in the UK has fallen from 4.85 per 10,000 in 
2009 to 2.29 per 10,000 in 2013.
19
   In addition, the low prevalence of CDAD could 
be due to short study time period and point prevalence nature of the study. 
 
Risk factors associated with CDI have been investigated in many studies. Prior 
antimicrobial use is a well known risk factor for developing CDI. Antimicrobials alter 
the healthy faecal microbiome, allowing C. diff to colonise, overgrow, and produce 
toxins if a C. diff exposure occurs before the faecal microbiome is able to return to a 
healthy state. Traditionally, clindamycin has been associated with CDI, and it remains 
an important predisposing risk factor today.
20
 Exposure to gastric acid suppressive 
agents has also been identified as a risk factor associated with CDI.
21
 The mechanism 
of action of gastric acid suppression in the causal pathway of CDI is not fully known. 
As an obligate anaerobe, the vegetative cells of C. diff die within minutes after 
exposure to air. Therefore, C. diff acquisition involves the ingestion of C. diff spores, 
which are resistant to gastric acid. Rather than being in the causal pathway of CDI, 
gastric acid suppression may be a surrogate marker for patients at increased risk of 
CDI.
22 
Due to limited case in the present study, we were not able to analyse potential 
risk factors for CDAD but, apart from the traditional risk factors, our study found 
summer season and polypharmacy may be additional risk factors for AAD.   
 
This study has some limitations. Firstly, the present study did not judge 
whether the use of antibiotic was appropriate therefore it may overestimate the use of 
antibiotic. The selection of the SCIC was at discretion of the study authors. However, 
the SCI centre (National Spinal Injuries Centre at Stoke Mandeville Hospital) selected 
is the largest SCI centre (115 beds) in the UK and represented approximately 25% of 
9 
the SCIC’s beds in the UK.  Therefore, results derived from this sample of SCICs 
could be considered representative or at least serve as a pilot study. To include one 
large SCIC may prevent the differences on antibiotic prescription and bowel 
management programme between SCICs. Previous research has found different 
definitions of diarrhoea have been used in different SCICs in the UK and other 
European SCI centres.
6
 Indeed, to use a standardised definition of diarrhoea would not 
just help in identifying and treating patients with SCI but also allowing bench 
marking with other SCI centres and to enable future AAD / CDAD research.  
 
Conclusions 
The present study found AAD is common in SCI patients and may be a risk factor for 
poorer outcome and increased hospital cost. A multicenter study is planned to 
establish the prevalence and risk factors for AAD / CDAD. 
 
Supplementary information is available on the Journal's website 
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